BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24282277)

  • 1. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling.
    Duffy DJ; Krstic A; Schwarzl T; Higgins DG; Kolch W
    Mol Cancer Ther; 2014 Feb; 13(2):454-67. PubMed ID: 24282277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
    Cortés C; Kozma SC; Tauler A; Ambrosio S
    Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK3 promotes arsenite-induced apoptosis via facilitation of mitochondria disruption.
    Watcharasit P; Thiantanawat A; Satayavivad J
    J Appl Toxicol; 2008 May; 28(4):466-74. PubMed ID: 17849503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
    Chen Y; Tsai YH; Tseng SH
    Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
    Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
    Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
    Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
    Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
    Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
    He J; Gu L; Zhang H; Zhou M
    Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells.
    Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Choi J
    PLoS One; 2013; 8(4):e60383. PubMed ID: 23565238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
    Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
    Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
    Molenaar JJ; Ebus ME; Geerts D; Koster J; Lamers F; Valentijn LJ; Westerhout EM; Versteeg R; Caron HN
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12968-73. PubMed ID: 19525400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival of tetraploid neuroblastoma cells.
    Gogolin S; Batra R; Harder N; Ehemann V; Paffhausen T; Diessl N; Sagulenko V; Benner A; Gade S; Nolte I; Rohr K; König R; Westermann F
    Cancer Lett; 2013 Apr; 331(1):35-45. PubMed ID: 23186832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.